Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Completed
- Conditions
- Acute Myocardial Infarction
- Registration Number
- NCT05974397
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This was a retrospective study using the Taiwan's National Health Insurance Research Database (NHIRD). The study employed two study designs for different purposes as follows:
* A cross-sectional analysis was conducted to explore the annual incidence trends.
* A longitudinal cohort study was conducted to assess baseline characteristics, treatment patterns, long-term healthcare utilization, and cause-specific mortality among incident AMI patients.
In each part, the study was conducted for AMI, and separately for ST-segment elevation and non-ST- segment elevation myocardial infarction (STEMI and NSTEMI)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 124018
Inclusion Criteria
Cross-sectional analysis:
- Patients aged 20 years and older.
- Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2020.
- The diagnosis of AMI/ STEMI/ NSTEMI was identified by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes and 10th revision (ICD-10-CM) codes.
- Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.
Longitudinal analysis:
Patients aged 20 years and older.
- Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2017.
- The diagnosis of AMI/ STEMI/ NSTEMI was identified by ICD-9-CM codes and ICD-10-CM codes. (The ICD-9-CM code and ICD-10-CM codes were the same as above)
- Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.
- The cohort entry date was defined as the admission date of incident AMI hospitalization, and the index date was defined as the discharge date of incident hospitalization.
Exclusion Criteria
None specified
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of AMI patients with comorbidities Up to 3 years Number of patients with treatment for STEMI Up to 3 years Number of NSTEMI patients with comorbidities Up to 3 years Number of STEMI patients with comorbidities Up to 3 years Length of hospital stay for STEMI patients Up to 3 years Number of patients with AMI in Taiwan 12 months Number of patients with treatment for AMI Up to 3 years Mean age of patients 12 months Number of mortalities among STEMI patients Up to 3 years Length of hospital stay for AMI patients Up to 3 years Number of STEMI patients with emergency room visits Up to 3 years Number of STEMI patients with hospitalizations Up to 3 years Number of male patients 12 months Year of patient entry into cohort 12 months Length of hospital stay for NSTEMI patients Up to 3 years Number of patients with STEMI in Taiwan 12 months Number of patients with NSTEMI in Taiwan 12 months Number of patients with treatment for NSTEMI Up to 3 years Number of mortalities among AMI patients Up to 3 years Number of mortalities among NSTEMI patients Up to 3 years Number of AMI patients with outpatient visits Up to 3 years Number of AMI patients with emergency room visits Up to 3 years Number of AMI patients with hospitalizations Up to 3 years Direct medical costs for AMI patients Up to 3 years Number of STEMI patients with outpatient visits Up to 3 years Direct medical costs for STEMI patients Up to 3 years Number of NSTEMI patients with outpatient visits Up to 3 years Number of NSTEMI patients with hospitalizations Up to 3 years Direct medical costs for NSTEMI patients Up to 3 years Number of NSTEMI patients with emergency room visits Up to 3 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Novartis
🇨🇳Taipei, Taiwan